IBI is an innovative hi-tech Swiss biomedical company focused on research, development and production of medical devices for tissue engineering and regenerative medicine: substitutes, grafts, 3D matrixes and 2D scaffolds.
IBI believes that regenerative medicine and tissue engineering represent the future for health.
IBI has strong competencies and core skills in processing materials for biomedical applications, used to develop proprietary technologies to build its new and innovative products.
IBI pays extreme attention to safety and quality: IBI is ISO13485 certified. SmartBone® is CE marked according to 93/42/CE Directive classified as a class III Medical Device.
Industrie Biomediche Insubri SA is a Swiss Company established under the Swiss Federal Law.
Via Cantonale 67
CH-6805 Mezzovico-Vira (Ticino)
VAT code: CHE-112.388.119 IVA
Registration number at the Chamber of Commerce of the Canton Ticino: CH-514.3.029.225-5
Swiss Company Register Identification Number: CHE-112.388.119
IBI is established as a privately owned company, under the Swiss Federal Laws.
IBI is among partners of the Italian/Swiss InterReg project “Clu.B.”, financed under the patronage of the European Commission by the Italian Regione Lombardia, the Swiss Federal Government and the Ticino Economic Development Office.
IBI starts selling SmartBone for lab use in cell therapies development for bone regeneration.
Phoenix|x-ray (a GE company) runs innovative microCT scans on SmartBone.
IBI welcomes Gianfranco Colomba as its C.E.O.
IBI opens its European Branch.
IBI obtains the approval for clinical studies on SmartBone.
Agire Invest SA, the Development Agency of the Ministry of Economics of the Canton Ticino, joins IBI shareholders entering into equity as an Investor.
IBI secures a second investment round from Fondazione “Filippo Serpero”.
IBI obtains ISO 13485 and ISO 9001 certifications and its SmartBone obtains the CE mark for human use!
The Compagnie Financiere St. Exupéry SA has become one of IBI’s shareholders and has expressed Dr. Claudio Girardi as director and vice-president.